DOI QR코드

DOI QR Code

Survival Analysis of Breast Cancer Patients in Northwest Iran

  • Ziaei, Jamal Eivazi (Breast Cancer Group, Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Sanaat, Zohreh (Breast Cancer Group, Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Asvadi, Iraj (Breast Cancer Group, Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Dastgiri, Saeed (Breast Cancer Group, Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Pourzand, Ali (Breast Cancer Group, Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Vaez, Jalil (Breast Cancer Group, Hematology and Oncology Research Center, Tabriz University of Medical Sciences)
  • Published : 2013.01.31

Abstract

Background: Breast cancer is the most frequently occurring cancer among Iranian women; however limited studies have been conducted to address survival rates. Objective: The objective was to examine survival rates in Tabriz (Northwest of Iran) and comparing with those of data reported from other cities and countries. Methods: Survival rates were calculated for one, three, five, seven and ten years for 271 breast cancer patients referred to one university clinic during 1997-2008. Results: Survival analysis demonstrated a lower survival rate compared to western countries. Conclusions: Survival rates for our patients are similar/better than other cities in Iran, but lower than certain European countries and the US. Further studies with a higher number of patients are now required.

References

  1. Kheradmand A, Ranjbarnovin N, Khazaeipour Z (2010). Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients. World J Surg Oncol, 8, 30. https://doi.org/10.1186/1477-7819-8-30
  2. Mansell J, Monypenny IJ, Skene AI, et al (2009). Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat, 117, 91-8. https://doi.org/10.1007/s10549-008-0291-z
  3. Mousavi M, Mohaghegghi MA, Mousavi- Jerrahi A (2006). Burden of breast cancer in Iran: A study of the Tehran population based cancer registry. Asia Pac J Cancer Prev, 7, 571-4.
  4. Rastad H, Khanjani N, Khandani BK (2012). Causes of delay in seeking treatment in patients with breast cancer in Iran: a qualitative content analysis study. Asia Pac J Cancer Prev, 13, 4511-5. https://doi.org/10.7314/APJCP.2012.13.9.4511
  5. Rezaianzadeh A, Peacock J, Reidpath D, et al (2009). Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran. BMC Cancer, 5, 168.
  6. Sadjadi A, Hislop T, Bajdik C, et al (2009). Comparison of breast cancer survival in two population: Ardabil, Iran and British Columbia, Canada. BMC Cancer, 9, 381. https://doi.org/10.1186/1471-2407-9-381
  7. Ugnat AM, Xie L, Morriss J, Semenciw R, Mao Y (2004). Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. Br J Cancer, 22,1138-43.
  8. Vahdaninia M, Montazeri A(2004). Breast cancer in Iran: a survival analysis. Asia Pac J Cancer Prev, 5, 223-5.
  9. Vostakolaei FA, Broeders MJ, Rostami N (2012). Age at diagnosis and breast cancer survival in iran. Int J Breast Cancer, 10, 517976.
  10. Burstein HG, Harris JR, Morrow M (2011). Malignant tumors of the breast. In Cancer , Principle and practice of oncology', Vincent T. Devita, Jr. Theodore S. Lawrence, Steven A, Rosenberg, Wolters Kluwer company. USA P: 1428.
  11. Curado MP (2011). Breast cancer in the world: incidence and mortality. Salud publica Mex, 53, 372-84.
  12. Eivazi ZJ, Pourzand A, Baiat A, et al (2012). Pattern of metastasis and survival of breast cancer patients, a preliminary report from northwest Iran. Asia Pac J Cancer Prev, 13, 937-40. https://doi.org/10.7314/APJCP.2012.13.3.937
  13. Faradmal J, Talebi A, Rezaianzadeh A, et al (2012). Survival analysis of breast cancer patients using cox and frailty models. J Res Health Sci, 13, 127-30.
  14. Fouladi N, Amani F, Harghi A, Nayebyazdi N (2011). Five year survival of women with breast cancers in Ardabil, northwest of Iran. Asia Pac J Cancer Pre, 12, 1869-71.
  15. Harirchi I, Kolahdoozan S, Karbakhsh M, et al (2001). Twenty years of breast cancer in Iran: downstaging without a formal screening program, Ann Oncol, 22, 93-7.
  16. Hemminki K, Mousavi SM, Sundquist J, Brandt A (2011). Does the breast cancer age at diagnosis differ by ethnicity? A study on immigrants to Sweden. Oncologist, 16, 146-54. https://doi.org/10.1634/theoncologist.2010-0104
  17. Hislop TG, Bajdik CD, Regier MD, Barroetavena MC (2007). Ethnic differences in survival for female cancers of the breast, cervix and colorectum in British Columbia, Canada. Asia Pac J Cancer Prev, 8, 1-6.

Cited by

  1. Survival Time and Molecular Subtypes of Breast Cancer after Radiotherapy in Thailand vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10505
  2. Fitting Cure Rate Model to Breast Cancer Data of Cancer Research Center vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7923
  3. Plasma Circulating Cell-free Nuclear and Mitochondrial DNA as Potential Biomarkers in the Peripheral Blood of Breast Cancer Patients vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8299
  4. Survival Analysis of Patients with Breast Cancer using Weibull Parametric Model vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8567
  5. Survival Rates for Breast Cancer in Iranian Patients: a Meta-Analysis vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2223
  6. Expression of Breast Cancer Subtypes Based on the Most Important Biomarkers: Comparison of Clinicopathological Factors and Survival vol.20, pp.1, 2018, https://doi.org/10.5812/ircmj.57931